chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Later on the day of vaccination I started feeling fatigue & pain on the site of the injection. I had continues fatigue & muscle pain this lasted about 5-6 days. On 12/28/2020 I started noticing that I developed shingles on my right side of forehead also experiencing pain till current. I saw my doctor on 12/28/2020 & prescribed medication.
Patient received vaccine and them 8 1/2 hrs later had a Febrile seizure went to ER.
Cellulitis symptoms immediately after injections, intense pain, limited amount of movement in both arms. Inability to rotate or lift arms or dress self w/out assistance. Currently in pain w/ongoing stiffness in shoulders, arms, wrists and hands. This has been going on for 9 months now.
Patient developed chest pain and was evaluated in the ED. After work-up, diagnosis of pericarditis was given.
The patient experienced severe pain in the shoulder and neck area with numbness and tingling down to the fingers in the right hand. This progressed over 2 years to pain in the right elbow. Tingling and numbness was experienced in both hands and fingers. At initial onset the patient was treated with pain medication and referred to a chiropractor. The patient continued with periodic episodes of pain and was later diagnosed with rheumatoid arthritis.
Patient reports that she is having terrible upper left arm pain that prevents her from moving her left arm. Also reports that she is having chest tightness. Patient denies any of these symptoms with the first dose of the Pfizer vaccine.
patient felt lightheaded and then passed out. She also felt a little naseuous. Patient was laid down in supine position with feet elevated and given ice packs. Patient threw up and after 30 minutes felt better and left
This spontaneous report as received from a pharmacist refers to a female patient of unknown age with anxiety, hypertension and penicillin allergy. On 09-FEB-2010 the patient was vaccinated with ZOSTAVAX, (lot number reported as 0875Y and expiration date 20-DEC-2010, the reporter was not sure about lot number), (anatomical location unspecified), 1 dose via subcutaneous. Concomitant therapies included hydrochlorothiazide (manufacturer unknown) and ramipril (manufacturer unknown). On an unspecified date in July 2013 (reported as within the last 7 days) the patient experienced shingles. The patient sought medical attention and it was administered NORCO for pain. The outcome of shingles was unknown. Additional information has been requested.
Patient with an Estimated Date of Delivery: 4/24/21 who presented for scheduled repeat c-section and bilateral salpingectomy at 39w2d gestation. Hospital admission within 6 weeks of receiving the COVID vaccine.
Vaccinated 3/9/09 - on 3/14/09 mother noted fine red rash on face, abdomen, neck trunk & upper legs, No treatment.
Chills, fatigues, hives x 7 days. Treated self with Benadryl.
The pt experienced upper arm redness and warmth to the touch at the site of injection. No discoloration or irritability. Brought to health department.
Initial unsolicited report received from a consumer (patient's mother) on 03 Nov 2016. This case involves a 15-year-old female patient who was vaccinated with a dose of Fluzone QIV (Batch number, expiration date, dose and dose in series were not reported) intramuscularly in the deltoid on 01 Nov 16. Patient's medical history as pre-existing physician diagnosed allergies, birth defects, medical conditions (specify) was reported as celiac disease, asthma and Gastro esophageal Reflux Disease (GERD). Illness at the time of vaccination was reported as not acutely ill. Concomitant medications were not reported. Any other vaccinations within four weeks of vaccinations were also not reported. On 02 Nov 2016, one day following the vaccination, the patient experienced a flare up of her celiac disease symptoms and dizziness. The patient experienced abdominal cramping, diarrhea and fatigue. Parent stated no plans to have her daughter evaluated by physician. Laboratory investigations and corrective treatment were not reported. The outcome of events was reported as unknown. List of documents held by sender: none.
1st day: Pain at injection site, muscle aches (mostly upper body), headache, chills, sleeplessness. 2nd day: Headaches, muscle aches, brain fog, persistent neck pain on left side at base of neck. 3rd day forward: Still having headaches and the neck pain, the neck pain seems to be getting worse. I have not called a doctor yet, since overall the symptoms are mild to moderate.
This spontaneous report was received from a licensed practical nurse referring to a patient of unknown age and gender. The patient's pertinent medical history, concurrent conditions, concomitant therapies and drug reactions/allergies were not reported. On 01-FEB-2017, the patient was vaccinated with a dose of ZOSTAVAX 0.5 ml lot # M035692, expiration date: 07-OCT-2017, subcutaneously for prophylaxis; nevertheless, the reporter stated that the vaccine was reconstituted with 0.5 ml of diluent (manufacturer unknown)  rather than full contents of diluent (lot # reported as L008523, expiration date 26-NOV-2017). No side effects were reported. Additional information has been requested.
Aches, Chills, Nausea, vomiting, fatiuge - 48 hours. chest tightness- 6 hours
I have noticed that both my feet have been a little chilly since the shot. It comes and goes but is noticeable.
Patient felt like passing out, so patient was asked to sit on chair. After a while patient passed out for at least  for 30 seconds. Pharmacy called 911. When patient was awake he started vomiting.  The  EMTs arrived and took patient's vital signs and transported patient to hospital. Patient seemed  much better at the time of transport.
Day after vaccine - fever 100.9, chills, body aches, fatigue, headache.
The medical assistant administering the vaccine had a needle-stick injury; The medical assistant administering the vaccine had a needle-stick injury; The medical assistant administering the vaccine had a needle-stick injury; This spontaneous report has been received from a prescriber nurse concerning a female patient of unknown age, who was also a medical assistant.  The patient's medical history, concurrent conditions and concomitant medications were not reported.  On 22-AUG-2022, while the patient was vaccinating a child with a dose of  Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) (Dose, route of administration, Lot # and expiration date were not provided), she had a needle stick injury (Injury associated with device) (Accidental exposure to product) (Occupational exposure to product).  At the time of reporting, the outcome of the events was not provided by the reporter. No additional adverse events were reported.   The causal relationship between Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) to Injury associated with device was not reported.
Information has been received from a registered nurse referring to an unspecified patient of unknown age and gender. Information regarding the patient's medical history, concurrent conditions and concomitant medications was not provided. The nurse reported that on 30-MAY-2018, the patient was inadvertently vaccinated with an expired dose of VAQTA, (lot # N005274, expiry date 03-APR-2018) (strength, dose and route of administration were not reported). No adverse effects were reported.
diarrhea started on 7/17/99 until 7/21/99;no fever;
Onset of unilateral (right) chronic facial pain eventually diagnosed as trigeminal neuralgia/ pain associated with trigeminal neuralgia diagnosis; This is a spontaneous report received from a contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 23-year-old female patient (not pregnant) received the third dose of bnt162b2 (BNT162B2) via an unspecified route of administration, administered in the left arm, on an unspecified date (batch/lot number: unknown) as DOSE 3 (BOOSTER), SINGLE for COVID-19 immunization. Relevant medical history included: "Childhood Guillain-Barre" (unspecified if ongoing), notes: early infancy, 4MO, believed to be triggered by routine childhood vaccinations; "Routine childhood vaccinations" (not ongoing); "Known allergies: Tomatoes" (unspecified if ongoing). Patient was not diagnosed with COVID-19 prior to vaccination. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (first dose, via an unspecified route of administration, administered in the left arm (batch/lot number: EN5318) as DOSE 1, SINGLE) for COVID-19 immunization; Bnt162b2 (second dose, via an unspecified route of administration, administered in the left arm (batch/lot number: EL3249) as DOSE 2, SINGLE), for COVID-19 immunization. The patient did not receive other vaccine in four weeks. The following information was reported: TRIGEMINAL NEURALGIA (medically significant) with onset 10Dec2021, outcome "not recovered" described as "Onset of unilateral (right) chronic facial pain eventually diagnosed as trigeminal neuralgia/ pain associated with trigeminal neuralgia diagnosis." The event was evaluated at the physician office visit and emergency room visit. Therapeutic measures were taken as a result of trigeminal neuralgia which included Gabapentin, Prednisone, antibiotics (as reported). The clinical course was reported as follows: Onset of unilateral (right) chronic facial pain (eventually diagnosed as trigeminal neuralgia) shortly after receiving third dose of vaccination. Pain associated with trigeminal neuralgia diagnosis persists though lessened by prescription of 300mg Gabapentin 3 times per day. Patient was not tested for COVID-19 post vaccination.  The batch/lot number for bnt162b2 was not provided and will be requested during follow up.
Patient received Hep A and Pneumo 23 on right arm on 09/28/8. Patient states on Sunday woke up with pain on his arm. States pain goes down his arm and radiates up his neck. No swelling, redness, or skin changes. patient takes one or two ALEVE as needed for pain. In office today 11 days later and still having only pain. Spoke to CDC stated 1 in 1 million have pain for longer periods of time.
This non-serious spontaneous case, initially received from other non-healthcare professional (consumer) via pharmaceutical manufacturer Novartis (PVI-US-2018-001621) on 13-Jun-2018, concerning a female patient of body weight 189 pounds and height of 65 inches. The patient's current conditions included vitamin D deficiency, anemia, depression, migraines and hypothyroidism (since unspecified dates). The patient had been allergic to AMOXIL, tramadol and BENADRYL. On an unspecified date, the patient was administered with influenza vaccine (dose, route of administration, anatomical location, batch number, expiry date, manufacturer and trade name: not reported). On an unspecified date, after vaccination, the patient experienced allergies (unspecified). At the time of this report, the outcome of the event was not reported. The reporter considered the causality of the event as related to suspect vaccine.
Information has been received from a nurse concerning a 22 month old female patient who was vaccinated orally with three doses of ROTATEQ (lot#s follow as 660682/0574X, 660880/0923X, 662618/0925X) respectively on 04-AUG-2008, 06-OCT-2008 and 03-DEC-2008. On an unspecified date in the week of 29-MAR-2010, the patient was tested positive for rotavirus after being fully vaccinated with ROTATEQ. The patient was brought to the doctor's office and was treated with diet and fluids. At the time of this report, the patient was recovering. This is one of several reports from the same source. This is a consolidation of two reports concerning the same patient. Additional information has been requested.
This spontaneous report was received from a registered nurse regarding unspecified number of children of unknown age and gender. The medical history of patients and their concurrent conditions were not reported. On an unknown date unspecified amount of children were vaccination with (Oka/Merck) VARIVAX (lot # L0282768, expiry date 28-JUL-2017); L012038, expiry date 07-APR-2017; L035126, expiry date 14-SEP-2017) dose, route unknown. The nurse reported that (Oka/Merck) VARIVAX went through defrost cycling of the freezer. The temperature ranges to which product was exposed during defrost cycling of the freezer were -14.2 C, -14.4 C, -14.7 C, -15.1 C, -13.4 C. The time frame of exposure was cumulative nonconsecutive total combined 5 hours and 45 minutes. It was reported that (Oka/Merck) VARIVAX was not subjected to previous temperature excursion. Concomitant medications were not reported. No adverse event were reported. Product quality complaint (PQC) was not filed. Additional information has not expected as reporter did not wish to contact further.
Patient recieved the MCV4 in the L deltoid and HPV in the R deltoid. When the patient got up from the table the color drained from her face and she asked if she should "feel funny?" Here ears began ringing and everything went black. She fainted to the floor and her legs were fluttering from her legs being bent. Here legs were down. The adminstering nurse helped her to the floor and put her arms around the patient. The episode lasted no more than a minute to a minute to a minute and a half.
Suspected Vaccination Failure; Got them last Dec; Pain was horrible; This case was reported by a consumer via interactive digital media and described the occurrence of suspected vaccination failure in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 2nd dose of Shingles vaccine and the 1st dose of Shingles vaccine. In December 2020, unknown after receiving Shingles vaccine and Shingles vaccine, the patient experienced vaccination failure (serious criteria GSK medically significant), shingles and pain. On an unknown date, the outcome of the vaccination failure, shingles and pain were unknown.   It was unknown if the reporter considered the vaccination failure, shingles and pain to be related to Shingles vaccine and Shingles vaccine.  Additional details were reported as follows: The case was reported by the patient. The age at vaccination was not reported. The patient had two Shingles shots and got the shingles last December. The patient stated that he/she was lucky whereas the patient had two shots that only got one spot, however the pain was horrible. As per the patient, it was not fun at all and he/she need to got another booster shot soon. This case was considered to be a suspected vaccination failure case, as the details regarding laboratory confirmation for shingles and time to onset were unknown.
On 9/24/21,  5 months after last injection, I woke up in AFIB and ended up going to the ER and being admitted for overnight monitoring in the cardiac unit. After taking Cardizem, my HR returned to normal at 3am on 9/25/21.
Extremely sore right arm, long-lasting headache, achiness, fatigue, sore shoulder muscles. Headache and achiness began overnight, fatigue set in about 24 hours after vaccination.
This spontaneous report as received from a nurse practitioner refers to two unspecified patients of unknown age and gender. The patient's pertinent medical history, concurrent conditions and concomitant medications were not reported. No previous drug reactions or allergies were reported. On an unknown date the patients were vaccinated with improperly stored ROTATEQ (dosing details were not reported) (lot # M044399, expiry date: 25-JUN-2018) orally for prophylaxis at a temperature of 34.5 degree farenheit for a time frame of 25 hours (incorrect product storage). There were no previous temperature excursions reported. The call was because of a data logger. No adverse effects reported. There was no product quality complaint involved.
This spontaneous report as received from a Medical Assistant refers to a male patient of unknown age. The patient received the first dose of RECOMBIVAX HB (therapy type, dose, route, lot# and expiration date  were not reported) in November 2011, the second dose of RECOMBIVAX HB (therapy type, dose, route, lot# and expiration date were not reported) on 10-JAN-2012 and the third dose of RECOMBIVAX HB (therapy type, dose, route, lot# and expiration date were not reported) on 27-FEB-2012. The reporter stated that the patient "received the 3rd dose of RECOMBIVAX HB too quick, it was only 6 weeks after the 2nd". No adverse effects were reported. No PQC (product quality complaint) was involved. Additional information is not expected, because there is no consent for further contact.
Felt ferverish (without a fever). Muscle soreness, muscle weakness, lack of fine muscle control (had trouble writing/typing). Symptoms got worse and gradually subsided by 11/06/2012 (1 week).
I got a sore throat and a severe cough with a runny nose starting about a month after the vaccination.  I tested 3X for Covid and all were negative.  I didn't recover completely and kept coughing up phlegm.  On Nov 11 I tested positive for Covid with a rapid test.  I have now fully recovered
pt recvd vax & following 2nd dose of vax pt devel a rash which was generalized to rt arm & rt leg;No further details were provided;
Family and patient believe she had decompensation of mood/anxiety/delusions in weeks post vaccine  Symptoms are not new however, just worse. Other psychosocial stressors could be contributing.  Compliant with psych meds  They pressed for a report and thus I am complying.
About 13  minutes after receiving the vaccine experience extremely sudden nausea followed by dizziness and increased heart rate and blood pressure.  Was  monitored by onsite EMTs and given oxygen for about 45 minutes before my vitals began to come to a level where they felt I could go home.  Monitored my own heart rate at home via a Fitbit and it remained in the low 90s until around 9pm; by morning it was in my normal range.  Was completely weak and stayed in bed for about 10 hours following the vaccine.
Injection site tender to touch; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Injection site tender to touch) in a 55-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 046A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Mar-2021, the patient experienced VACCINATION SITE PAIN (Injection site tender to touch). At the time of the report, VACCINATION SITE PAIN (Injection site tender to touch) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.       No concomitant medications were reported.   No treatment information was provided.   This case was linked to MOD-2021-076201 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 21-Jul-2021: Follow up received - Event Outcome updated.
The pt a 50 y/o male received his first Moderna Vaccination at approximately 1518 (site L-deltoid). During the patients 15 minute observation period his nose began to bleed. The bleeding was isolated to the left nostril  and was capillary bleeding only. The pt was concerned the bleeding was caused due to the vaccine he received. The pt was instructed how to pinch his nose to clot the bleeding and instructed to lean his head forward and not back. The pts nose quickly clotted and bleeding stopped. Upon observation of the nasal canal a scab was noted on the septum wall. Pt stated he has been outside a lot lately and humidity was very low. Pt denied any pain, recent trauma, headache, dizziness or being on any blood thinners. Once bleeding stopped the pt felt fine and was cleared to leave. Outcome- Supportive care was provided, pt concerned resolved and pt required no further interventions or a higher level of care.
Extreme fatigue, N/V, body aches, chills, dry cough, eyeballs hurt...flu like symptoms; She stated that she was very close to going to the ER yesterday but didn't. Getting a covid test.
Urticaria from shoulder to elbow; Arm warm to the touch; Arm swollen; severe itching; Left upper arm - red; Arm was sore; Arm was bruised/little discolored; This spontaneous case was reported by a health care professional and describes the occurrence of VACCINATION SITE BRUISING (Arm was bruised/little discolored), URTICARIA (Urticaria from shoulder to elbow), VACCINATION SITE WARMTH (Arm warm to the touch), VACCINATION SITE PAIN (Arm was sore) and VACCINATION SITE SWELLING (Arm swollen) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Shellfish allergy and Constipation chronic. Concomitant products included LINACLOTIDE (LINZESS) and MACROGOL 3350 (MIRALAX) for Constipation, BIFIDOBACTERIUM INFANTIS (ALIGN) for an unknown indication.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE BRUISING (Arm was bruised/little discolored) and VACCINATION SITE PAIN (Arm was sore). On 14-Jan-2021, the patient experienced URTICARIA (Urticaria from shoulder to elbow), VACCINATION SITE WARMTH (Arm warm to the touch), VACCINATION SITE SWELLING (Arm swollen), VACCINATION SITE PRURITUS (severe itching) and VACCINATION SITE ERYTHEMA (Left upper arm - red). The patient was treated with LORATADINE (CLARITIN [LORATADINE]) (oral) at a dose of 10 mg and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. On 09-Jan-2021, VACCINATION SITE PAIN (Arm was sore) had resolved. On 19-Jan-2021, VACCINATION SITE SWELLING (Arm swollen) and VACCINATION SITE PRURITUS (severe itching) had resolved. On 20-Jan-2021, VACCINATION SITE BRUISING (Arm was bruised/little discolored), URTICARIA (Urticaria from shoulder to elbow), VACCINATION SITE WARMTH (Arm warm to the touch) and VACCINATION SITE ERYTHEMA (Left upper arm - red) had resolved.        mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosing remained unchanged.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered VACCINATION SITE SWELLING (Arm swollen) to be possibly related. No further causality assessments were provided for VACCINATION SITE BRUISING (Arm was bruised/little discolored), URTICARIA (Urticaria from shoulder to elbow), VACCINATION SITE WARMTH (Arm warm to the touch), VACCINATION SITE PAIN (Arm was sore), VACCINATION SITE PRURITUS (severe itching) and VACCINATION SITE ERYTHEMA (Left upper arm - red).    This case was linked to MOD-2021-076807 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 14-Apr-2021: Added patient demographics, stop date of events. Updated the concomitant medications and event outcome.
Pt c/o feeling dizzy, decided to lie on ground BP 110/60; HR 80; RR 22. Vital signs stable. Drank water. Felt better in 5 minutes. Discharged home in stable condition
Beginning five days after vaccine administered: Extreme swelling  on lower eyelids and on foreskin of penis.   Penile symptom resolved  within a week; eyelid swelling persists.  Concurrently, widespread dermatitis (hives?) over most of body: most severe on both sides of abdomen and under both arms and legs.  Extreme itchiness, especially at night.  Was prescribed 5-day run of Prednizone at hospital Emergency Room on 1/31 , with minimal relief.  Dermatological symptoms persisting as of today 2/13.
Patient broke out in rashes across the right side of his body. The injection site was a baseball size bright red  hard lump and  hot to touch. His entire right inside  forearm was a raised red thickened bumpy skin with 5-6 puss leasions that was draining a clear fluid. Patient's torso was a bright red rash-and every time he exerts himself his rash carries up to the chest and acrosss entire back. This has been very hard on Patient he has become sad and withdrawn since getting this rash.